Enterovirus Infections  >>  sofosbuvir/velpatasvir  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sofosbuvir/velpatasvir / Generic mfg.
NCT02480712: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) and Human Immunodeficiency Virus (HIV)-1 Coinfection

Completed
3
107
US
SOF/VEL, GS-7977/GS-5816, Epclusa®
Gilead Sciences
Hepatitis C Virus Infection
04/16
06/16
GS-US-342-1522, NCT02722837 / 2015-003001-42: Efficacy and Safety of Sofosbuvir/Velpatasvir Fixed-Dose Combination in Participants With Chronic Hepatitis C Virus Infection

Completed
3
119
Europe, RoW
SOF/VEL, GS-7977/GS-5816, Epclusa®
Gilead Sciences
Hepatitis C Virus Infection
06/17
09/17
GS-US-342-1521, NCT03074331: Sofosbuvir/Velpatasvir Fixed Dose Combination for 12 Weeks in Adults With Chronic Hepatitis C Virus (HCV) Infection

Completed
3
130
RoW
SOF/VEL, Epclusa®, GS-7977/GS-5816
Gilead Sciences
Hepatitis C Virus Infection
02/18
02/18

Download Options